

VolitionRx

08:05 14 May 2020

VolitionRx to share data on enhanced Nu.Q Capture, Nu.Q Assay performance in detecting lung and blood cancers at ASCO meeting

VolitionRx Limited (NYSEAMERICAN:VNRX), an epigenetics company developing easy to use and cost-effective blood tests, announced Thursday that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) annual meeting.

The Austin, Texas-based firm said the first abstract presented will reveal initial data demonstrating the ability of Volition's sample-enrichment tool, Nu.Q Capture, to separate short and long nucleosomes in clinical colorectal cancer samples to enable the concentration of tumor-derived nucleosomal markers prior to analysis.

The other two abstracts will provide new performance data for Volition's Nucleosomics Nu.Q technology in the early detection of lung cancer and blood cancer.

READ: VolitionRx closes 1Q with \$12M in cash while studying Nu.Q blood test as potential coronavirus diagnostic tool

Data from a pilot study, the first published results for Volition's Nu.Q Capture program, showed that Nu.Q Capture technology successfully demonstrated enrichment of circulating tumor nucleosomes and tumor DNA (ctDNA). The data clearly showed the separation of short and long nucleosomes from both cancer cell lines in a laboratory setting, and in clinical colorectal cancer patients versus healthy controls.

"Effective removal of most 'healthy/long' nucleosomes creates an enriched sample allowing for more accurate measurement of cancer nucleosomes," Dr Mark Eccleston, who is the business development director and a founding scientist at Volition, said in a statement.

"Similarly, the removal of most 'healthy/long' nucleosome-associated DNA can also enhance detection of cancer using ctDNA technologies. These data are a really positive sign of the potential of Nu.Q Capture as a valuable tool to enable improved and earlier detection of cancer," he added.

For more information about the abstracts readers can watch this short video: <https://youtu.be/ypzzfpnvC5w>.


The study, conducted with Dr Anne Sibille and the team at Liege University Hospital, Belgium, aimed to assess the performance of a Nu.Q assay in discriminating both between lung cancer and healthy controls, and between lung cancer and Chronic Obstructive Pulmonary Disease (COPD).

A pilot study of 142 subjects demonstrated that Nu.Q assays could not only discriminate lung cancer versus healthy controls with an Area Under the Curve (AUC) of 88% but also between lung cancer and COPD with an AUC of 85%. The AUC is an industry-accepted measure of the effectiveness of an assay whereby 100% is the most accurate.

Price: 3.26

Market Cap: \$156.22 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	6.11	2.22

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. .

action@proactiveinvestors.com

Commenting on the study, Dr Marielle Herzog, who is the research and development director at Volition, said: "Lung cancer is not only the most prevalent cancer, but it is also the most deadly, responsible for over 1.75 million deaths worldwide each year."

"It's diagnosis currently relies on invasive methods and often occurs at a late stage of disease, explaining its poor outcome. Our hope is that a blood-based test could aid earlier diagnosis."

The pilot study investigated the circulating levels of intact nucleosomes containing the histone H3.1 isoform (Nu.Q-H3.1) in a variety of solid tumors including Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, and in healthy subjects.

The results showed elevated levels of Nu.Q-H3.1 in patients diagnosed with cancers.

"Elevated nucleosome levels have been reported for a number of diseases. These encouraging early results indicate that levels of Nu.Q™-H3.1 are particularly elevated in haematological cancers. These data show that Nu.Q technology may be a useful diagnostic tool warranting further study," said lead author, Dr Jason Terrell, who is the chief medical officer at Volition.

For more information about this abstract please watch this video <https://youtu.be/8QYDGPIA4EY>

The abstracts will be available to view starting at 5:00 pm ET on May 13 on the ASCO meeting library.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).